Emanuel de Duonni

Emanuel De Duonni is an Executive Director and Global Asset Head at Biogen, specializing in SKYCLARYS and Friedreich’s Ataxia since January 2018. With a strong background in customer and market insights, Emanuel has led significant initiatives in life cycle management, long-term strategy, and customer experience across various therapeutic areas. Prior experience includes leadership roles at Novo Nordisk, where Emanuel managed successful brand launches and complex projects in the diabetes, obesity, and hemophilia sectors. Educational qualifications encompass advanced degrees from esteemed institutions, including a joint MBA/Law program at McGill University and a Master of Science from Copenhagen Business School.